COMPANY

Prelude Therapeutics

HQ: Wilmington, DE source · preludetx.com ↗ · Mid-Atlantic

1 open job · last seen Oct 23, 2026 · 14 sources

Prelude Therapeutics applies its expertise in cancer biology and medicinal chemistry to identify targetable intervention points in cancer signaling pathways amenable to investigational small molecule-based therapies. From company website Source · checked 2026-10-19

Sources for this description (1)

Prelude Therapeutics applies its expertise in cancer biology and medicinal chemistry to identify targetable intervention points in cancer signaling pathways amenable to investigational small molecule-based therapies.
- “Instead, Prelude applies its deep expertise in cancer biology and medicinal chemistry to identify targetable intervention points in cancer signaling pathways amenable to investigational small molecule-based therapies.” https://preludetx.com/science/overview/ (2026-10-19)

Therapeutic area: cancer

Modality: small molecule

Keywords: cancer oncology Non-small Cell Lung Cancers Sarcoma Esophageal Cancer SMARCA4 Gene Mutation Marginal Zone Lymphoma Breast Cancer Acute Myeloid Leukemia Myelodysplastic Syndromes Polycythemia Vera Myelofibrosis Myeloproliferative Neoplasms Post-Polycythemia Vera Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis Primary Myelofibrosis Non-small Cell Lung Carcinoma SMARCA4 Mutation Esophageal Adenocarcinoma Esophageal Squamous Cell Carcinoma Gastric Adenocarcinoma Gastric Squamous Cell Carcinoma Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Squamous Cell Carcinoma Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) Mantle Cell Lymphoma Richter's Syndrome T-cell Lymphoma Diffuse Large B-cell Lymphoma Myeloid Malignancies Chronic Myelomonocytic Leukemia Myelodysplastic Syndrome MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome Glioblastoma Head and Neck Squamous Cell Carcinoma Malignant Mesothelioma Endometrial Cancer B-cell Non-Hodgkin Lymphoma Chronic Lymphocytic Leukemia

Location: Wilmington, DE · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Open jobs $90.0MRaised (2 yrs)12Trials (company is sponsor)

Hiring

Title	Location (from posting)	Employer posted	First seen
VP, Regulatory Affairs	PRELUDE OFFICE	Oct 1, 2026	Oct 11, 2026

See all 1 job

Timeline

Apr 29, 2026 Trial start 1: A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms source ↗
Apr 20, 2026 Raise Follow-on offering: $90M (total, as published), announced Apr 20, 2026. Source: SEC filing. source ↗
Nov 4, 2025 Partnership Partnership / licensing: $35M (upfront, as published); deal value up to $775M (kept separate from upfront), announced Nov 4, 2025. Source: SEC filing. source ↗
Jun 3, 2025 Trial start Phase 2: A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation source ↗
Nov 4, 2024 Trial start Phase 1: A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation source ↗
Sep 12, 2023 Trial start Phase 1: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies source ↗
May 2, 2023 Trial start Phase 1: PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation source ↗
Dec 27, 2022 Trial start Phase 1: A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors source ↗
Mar 22, 2022 Trial start Phase 1: PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies source ↗
Feb 14, 2022 Trial start Phase 1: A Study of PRT2527 in Participants With Advanced Solid Tumors source ↗
Aug 11, 2021 Trial start Phase 1: A Study of PRT1419 in Patients With Advanced Solid Tumors source ↗
Sep 28, 2020 Trial start Phase 1: A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies source ↗
Nov 6, 2019 Trial start Phase 1: A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas source ↗
Feb 11, 2019 Trial start Phase 1: A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies source ↗

Upcoming milestones

2028-04 (ESTIMATED) · 1 · A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms · NCT07469891

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $90.0M. Last 2 years.

Apr 20, 2026 Follow-on offering: $90M (total, as published), announced Apr 20, 2026. Source: SEC filing. source ↗
Nov 4, 2025 Partnership / licensing: $35M (upfront, as published); deal value up to $775M (kept separate from upfront), announced Nov 4, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 12

Record	Title	Phase	Status	Start	Primary completion
NCT07469891	A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms	1	Recruiting	Apr 29, 2026	2028-04 (estimated)
NCT06682806	A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation	Phase 2	Terminated	Jun 3, 2025	Jan 23, 2026 (actual)
NCT06560645	A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation	Phase 1	Terminated	Nov 4, 2024	Jan 28, 2026 (actual)
NCT05665530	A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies	Phase 1	Completed	Sep 12, 2023	Jun 12, 2025 (actual)
NCT05639751	PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation	Phase 1	Completed	May 2, 2023	Oct 1, 2025 (actual)
NCT05538572	A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors	Phase 1	Completed	Dec 27, 2022	Jun 26, 2024 (actual)
NCT05107856	PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies	Phase 1	Terminated	Mar 22, 2022	Jan 19, 2024 (actual)
NCT05159518	A Study of PRT2527 in Participants With Advanced Solid Tumors	Phase 1	Completed	Feb 14, 2022	Dec 6, 2023 (actual)
NCT04089449	A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas	Phase 1	Completed	Nov 6, 2019	Mar 28, 2023 (actual)
NCT03886831	A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies	Phase 1	Completed	Feb 11, 2019	Nov 16, 2022 (actual)
NCT04837677	A Study of PRT1419 in Patients With Advanced Solid Tumors	Phase 1	Completed	Aug 11, 2021	Feb 6, 2023 (actual)
NCT04543305	A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies	Phase 1	Completed	Sep 28, 2020	Mar 21, 2022 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗

Open jobs 1

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
VP, Regulatory Affairs	PRELUDE OFFICE	Oct 1, 2026	Oct 11, 2026	Executive

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Prelude Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18